Delivery Order SPE2DB24D2018-SPE2DB25FWWB2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injectors valued at $1,400.67. This firm fixed-price delivery order, with an ultimate completion date of November 18, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made without a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 31, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,722.90, with an ultimate completion date of January 2, 2026. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be performed from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,384.82 under a firm fixed price contract structure. This delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency (DLA) awarded a $1,516.36 delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of December 18, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $2,223.86 under a firm fixed price contract. The delivery order, which is a child contract under a larger vehicle, specifies a completion date of September 23, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. This award was not designated as a set-aside and was competitively awarded,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $3,681.48 under a firm fixed-price contract for Xyosted 75 mg/0.5 mL auto-injector pharmaceutical products. This competitive award, issued on October 30, 2025, with a completion date of October 31, 2025, represents a child contract with no set-aside designation. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector vials valued at $3,609.99 with completion targeted for August 19, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed price terms and is performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector units valued at $1,304.29 under a firm fixed price contract. This non-set-aside delivery order, which is scheduled for completion by September 5, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,078.57 with a firm fixed price structure. This is a competitively awarded, non-set-aside contract with an ultimate completion date of October 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB25FWWB2Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,272.07 on August 6, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of August 7, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This award was not designated as a set-aside contract and was competitively awarded through the federal procurement process. This delivery order represents a child contract action under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen serves as a prime pharmaceutical vendor for federal medical procurement, supplying a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The company's portfolio includes specialty pharmaceuticals, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic categories, making it a critical supplier for the Defense Health Agency and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/6/25 |